help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Journal of Clinical Endocrinology & Metabolism , doi:10.1210/jc.2006-2833
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bausch, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bausch, B.
Related Collections
Right arrow Adrenal and Hypertension
Right arrow Endocrine Oncology
The Journal of Clinical Endocrinology & Metabolism Vol. 92, No. 7 2784-2792
Copyright © 2007 by The Endocrine Society

Germline NF1 Mutational Spectra and Loss-of-Heterozygosity Analyses in Patients with Pheochromocytoma and Neurofibromatosis Type 1

Birke Bausch, Wiktor Borozdin, Victor F. Mautner, Michael M. Hoffmann, Detlef Boehm, Mercedes Robledo, Alberto Cascon, Tomas Harenberg, Francesca Schiavi, Christian Pawlu, Mariola Peczkowska, Claudio Letizia, Stefano Calvieri, Giorgio Arnaldi, Rolf D. Klingenberg-Noftz, Nicole Reisch, Ambrogio Fassina, Laurent Brunaud, Martin A. Walter, Massimo Mannelli, Graham MacGregor, F. Fausto Palazzo, Marta Barontini, Martin K. Walz, Bernhard Kremens, Georg Brabant, Roland Pfäffle, Ann-Cathrin Koschker, Felix Lohoefner, Markus Mohaupt, Oliver Gimm, Barbara Jarzab, Sarah R. McWhinney, Giuseppe Opocher, Andrzej Januszewicz, Jürgen Kohlhase, Charis Eng, Hartmut P. H. Neumann for the European-American Phaeochromocytoma Registry Study Group1

Departments of Nephrology (B.B., D.B., T.H., C.P., H.P.H.N.) and Laboratory Medicine (M.M.H.), University Medical Center Freiburg, D-79106 Freiburg, Germany; Institute for Human Genetics and Anthropology (W.B., J.K.), University of Freiburg, Freiburg, Germany; Center of Human Genetics (W.B., J.K.), Freiburg, Germany; Department of Maxillofacial Surgery (V.F.M.), University Hospital Eppendorf, Hamburg, Germany; Hereditary Endocrine Cancer Group (M.R., A.C.), Centro Nacional de Investigaciones Oncologicas, Madrid, Spain; Istituto Oncologico Veneto Instituto di Ricovero e Cura a Carattere Scientifico (F.S., G.O.), Padova, Italy; Department of Hypertension (M.P., A.J.), Institute of Cardiology, Warsaw, Poland; Departments of Clinical Sciences (C.L.) and Dermatology (S.C.), University of Rome La Sapienza, Rome, Italy; Department of Endocrinology (G.A.), Azienda Ospedaliero-Universitaria Ospedali Riuniti di Ancona, Ancona, Italy; Medical Clinic I (R.D.K.-N.), Universitätsklinikum Schleswig-Holstein, Campus Lübeck, Lübeck, Germany; Department of Endocrinology (N.R.), Ludwig-Maximilians-University of Munich, Munich, Germany; Department of Pathology (A.F.), University of Padova, Padova, Italy; Department of Digestive and Endocrine Surgery (L.B.), University Hospital Nancy, University of Nancy, Nancy, France; Institute of Nuclear Medicine (M.A.W.), Division of Endocrinology, University of Basel, Basel, Switzerland; Department of Clinical Pathophysiology, Endocrine Unit (M.Ma.), University of Florence, Florence, Italy; Blood Pressure Unit (G.M.), Department of Cardiovascular Sciences, St. George’s University, London, United Kingdom; Endocrine Surgery Unit (F.F.P.), Hammersmith Hospital, London, United Kingdom; Centro de Investigaciones Endocrinologicas-Consejo Nacional de Investigaciones Científicas y Técnicas (M.B.), Buenos Aires, Argentina; Department of Surgery (M.K.W.), Kliniken Essen-Mitte, Essen, Germany; Department of Pediatrics (B.K.), University of Essen, Essen, Germany; Department of Endocrinology (G.B.), Medizinische Hochschule, Hannover, Germany; Department of Pediatrics (R.P.), University of Leipzig, Leipzig, Germany; Department of Internal Medicine I-Endocrine and Diabetes (A.-C.K.), University of Wuerzburg, Wuerzburg, Germany; Department of Surgery (F.L.), Hospital of the German Red Cross, Berlin, Germany; Department of Nephrology and Hypertension (M.Mo.), University of Berne, Berne, Switzerland; Department of Visceral Surgery (O.G.), University of Halle, Halle, Germany; Department of Nuclear Medicine and Endocrine Oncology (B.J.), M. Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Gliwice, Poland; Genomic Medicine Institute (S.R.M., C.E.), Cleveland Clinic Foundation, Cleveland, Ohio 44195; and Department of Genetics (S.R.M., C.E.), Case Western Reserve University School of Medicine, Cleveland, Ohio 44106

Address all correspondence and requests for reprints to: Hartmut P. H. Neumann, Medizinische Universitätsklinik, Hugstetter Straße 55, D-79106 Freiburg, Germany. E-mail: neumann{at}med1.ukl.uni-freiburg.de.


   Abstract
Top
 Abstract
Introduction
 Patients and Methods
 Results
 Discussion
 References
 
Background: Neurofibromatosis type 1 (NF1) is a pheochromocytoma-associated syndrome. Because of the low prevalence of pheochromocytoma in NF1, we ascertained subjects by pheochromocytoma that also had NF1 in the hope of describing the germline NF1 mutational spectra of NF1-related pheochromocytoma.

Materials and Methods: An international registry for NF1-pheochromocytomas was established. Mutation scanning was performed using denaturing HPLC for intragenic variation and quantitative PCR for large deletions. Loss-of-heterozygosity analysis using markers in and around NF1 was performed.

Results: There were 37 eligible subjects (ages 14–70 yr). Of 21 patients with corresponding tumor available, 67% showed somatic loss of the nonmutated allele at the NF1 locus vs. 0 of 12 sporadic tumors (P = 0.0002). Overall, 86% of the 37 patients had exonic or splice site mutations, 14% large deletions or duplications; 79% of the mutations are novel. The cysteine-serine rich domain (CSR) was affected in 35% but the RAS GTPase activating protein domain (RGD) in only 13%. There did not appear to be an association between any clinical features, particularly pheochromocytoma presentation and severity, and NF1 mutation genotype.

Conclusions: The germline NF1 mutational spectra comprise intragenic mutations and deletions in individuals with pheochromocytoma and NF1. NF1 mutations tended to cluster in the CSR over the RAS-GAP domain, suggesting that CSR plays a more prominent role in individuals with NF1-pheochromocytoma than in NF1 individuals without this tumor. Loss-of-heterozygosity of NF1 markers in NF1-related pheochromocytoma was significantly more frequent than in sporadic pheochromocytoma, providing further molecular evidence that pheochromocytoma is a true component of NF1.


   Introduction
Top
 Abstract
 Introduction
Patients and Methods
 Results
 Discussion
 References
 
NEUROFIBROMATOSIS TYPE 1 (NF1) or von Recklinghausen disease (OMIM*162200), one of the most common autosomal dominant inherited disorders, is listed among the classic pheochromocytoma-associated syndromes, such as multiple endocrine neoplasia type 2 (MEN2), von Hippel-Lindau disease, and the recently defined paraganglioma syndromes (PGLs) type 1 (PGL1) and 4 (PGL4) (1, 2, 3, 4, 5). The disorder is characterized by pigmentary abnormalities and the neoplastic growth of neural crest-derived cells. Cardinal clinical features are multiple dermal neurofibromas, café-au-lait spots, axillary or inguinal freckling, and hamartomas of the iris. The diagnosis is based on clinical criteria initially established by the National Institutes of Health Consensus Development Conference (6) and revised by Gutmann et al. (7). By epidemiological methods, pheochromocytomas were found to occur in 0.1–5.7% of patients with NF1 and are, thus, more frequently observed in this disease than in the general population. When the prevalence of a specific clinical feature is relatively low, it is often debatable whether the phenotype of interest (in this case, pheochromocytoma) is a true component of a particular syndrome (in this case, NF1) (6, 7).

NF1 is caused by germline mutations of the NF1 gene, located on chromosome sub-band 17q11.2 (8, 9). It contains 57 coding exons spanning approximately 300 kb of genomic DNA encoding a 12,255-bp transcript with an open reading frame of 8,454 nucleotides and 2,818 amino acids, respectively (10). Three known alternative splice variants exist (11, 12).

Mutation detection in the NF1 gene remains a considerable challenge because of its large size and the presence of 36 pseudogenes (13, 14, 15, 16, 17, 18, 19). Because of the technical challenges and the low prevalence of pheochromocytoma in NF1, only a first-limited series of molecular genetically characterized patients with NF1 and pheochromocytoma has been presented so far by members of this study group (1).

According to Knudson’s two-hit theory, pheochromocytoma development requires biallelic inactivation (20), which was shown to be true in murine models (21) and humans (22) by loss-of-heterozygosity (LOH) of markers in the NF1 17q11.2 region and for silencing of neurofibromin expression (23).

We designed this current study to describe and document the full germline mutational spectra of NF1 in individuals with pheochromocytoma in the context of NF1. As a secondary end point, we sought to demonstrate a high frequency of somatic loss of the remaining wild-type NF1 allele in NF1-related pheochromocytomas because molecular evidence adjunctive to the epidemiological association that pheochromocytoma is a true component of NF1.


   Patients and Methods
Top
 Abstract
 Introduction
 Patients and Methods
Results
 Discussion
 References
 
Patients

Study subjects have been recruited among those in the Pheochromocytoma Registry founded separately in Freiburg and Warsaw, and combined in 1995 ("European-American Phaeochromocytoma Registry") (4, 5). In addition, because of the rarity of the co-occurrence, we extended the special NF1-associated pheochromocytoma group by asking for further contributions to the registry from collaborators in Europe and America should they have eligible subjects with pheochromocytoma and NF1. We also contacted the neurofibromatosis outpatient clinic and the Department of Maxillofacial Surgery at the University of Hamburg, all departments of dermatology in hospitals in Germany, many private practice dermatologists, and the German neurofibromatosis self-support group (only one accrued in this manner). The project was approved by the ethics committees of the respective institutions. All subjects provided informed consent in accordance with the accepted standards for each respective country.

Pheochromocytoma was defined as a tumor of the adrenal or of extra-adrenal sites of the abdomen and thorax. All neoplasias were histologically confirmed. Patients eligible for this study included those with pheochromocytoma and NF1 registered until June 30, 2006. For all subjects, demographic data as well as tumor number, location, and biology were registered. Presence of distant metastases were the criterion for malignant pheochromocytoma. Patients with NF1 were diagnosed according to the National Institutes of Health consensus criteria (6, 7). Clinical presentation of NF1 was classified as severe according to occurrence of malignant tumors, intellectual handicap, or epilepsy, or as mild if only associated with neurofibromas, axillary freckling, café-au-lait spots, and Lisch nodules, whereas additional features were regarded as intermediate NF1. EDTA-anticoagulated blood samples were obtained from each patient after obtaining informed consent. In addition, we collected fresh-frozen or paraffin-embedded tumor tissue of NF1-associated pheochromocytomas.

Molecular genetic analyses

DNA was extracted from peripheral blood lymphocytes by standard procedures. Mutation analysis of the NF1 gene was performed on genomic DNA from all 37 subjects with NF1-associated pheochromocytoma. Mutation analysis of the 57 exons and flanking intronic regions, as well as the untranslated 5' and 3' regions of the NF1 gene, required redesign of PCR primer pairs to exclude amplification of any of the 36 pseudogenes (13, 14, 15, 16, 17, 18, 19) (Table 1GoGo).


View this table:
[in this window]
[in a new window]

  		TABLE 1. Primers used for DHPLC

 

View this table:
[in this window]
[in a new window]

  		TABLE 1A.
 
Germline intragenic mutation scanning was carried out on each of the amplicons using denaturing HPLC analysis (DHPLC) (WAVE analysis system; Transgenomics, Paris, France). Samples displaying abnormal chromatographic patterns were subjected to bidirectional direct sequencing using a MegaBACE500 DNA sequencing machine (Amersham Biosciences, Freiburg, Germany).

Samples without germline intragenic mutations were candidates for large deletion and rearrangement analysis. Fine, exon-by-exon deletion detection was performed using a quantitative PCR approach with SYBR Green I detection (SYBR Green PCR Master Mix; QIAGEN, Hilden, Germany). The ABI Prism 7900 Sequence Detection System (PE Applied Biosystems, Foster City, CA) was used. The Sequence Detection System software (version 2.2.1; PE Applied Biosystems) was used to analyze the obtained data. All amplicons were 100–350 bp in length. Quantitative PCR was performed as described with the exception of an annealing temperature of 57 C (24, 25). Two subtelomeric amplicons were used as internal references. As a deletion negative control, genomic DNA from healthy, unrelated ethnically matched individuals was amplified. Melting curve analysis and gel electrophoresis were performed after the amplification to exclude the presence of nonspecific PCR products. Absolute quantification of the patient’s DNA was performed by interpolation of the threshold cycle number against the corresponding standard curve and normalized against a normal diploid reference genome. Ratio values of 1.0 indicated a diploid situation, whereas a ratio of 0.5 or 1.5 indicated a partial haploidy or partial triploidy, respectively.

The detected DNA missense alterations were investigated for pathogenicity by analyzing whether they were present in 100 healthy, unrelated, and ethnically matched subjects.

In silico analysis

An additional in silico analysis was performed for missense mutations/sequence variants that have not been previously described to evaluate the significance of the amino acid exchange. The ClustalW program (http://www.ebi.ac.uk/clustalw/) was used to generate a multiple sequence alignment among the sequences of human, mouse, chicken, and the Drosophila NF1 proteins.

Genotyping for LOH

LOH analysis was performed to test the hypothesis of inactivation of the remaining NF1 wild-type allele in tumor DNA. Genomic DNA from fresh-frozen or paraffin-embedded tumor tissue was extracted using standard procedures. LOH was determined by typing genomic DNA from 21-germline point mutation positive paired tumor and lymphocyte samples with four microsatellite markers (D17S1849, D17S1166, D17S798, and D17S1873) spanning the NF1 region. The markers were located centromeric, intragenic, and telomeric of the NF1 gene. DHPLC was used to investigate the LOH status.

Statistical analyses

Fisher’s 2-tailed exact test was used with {alpha} = 0.05 regarded as statistically significant.


   Results
Top
 Abstract
 Introduction
 Patients and Methods
 Results
Discussion
 References
 
A total of 37 unrelated patients with NF1 and pheochromocytoma showed a mutation of the NF1 gene (Table 2Go). Male to female ratio was 18:19. Mean age at pheochromocytoma diagnosis was 41 yr, with an age range of 14–70 yr. Of the 37 patients, 62% had solitary adrenal tumors, 27% had bilateral adrenal disease, and 5% had extra-adrenal abdominal pheochromocytomas. Malignant pheochromocytomas were identified in 6% (n = 2) of the patients. One patient had an extra-paraganglial malignant pheochromocytoma, a medullary thyroid cancer, and hyperparathyroidism, and he was RET mutation negative. Interestingly, an unrelated patient with the identical NF1 mutation had neither medullary thyroid cancer nor other features of MEN2 (Table 3Go). There were also three women with breast cancer (10%). These tumors are indicated in Table 3Go as "malignancies related to NF1."


View this table:
[in this window]
[in a new window]

  		TABLE 2. Mutations in 37 index cases with NF1 and pheochromocytoma

 

View this table:
[in this window]
[in a new window]

  		TABLE 3. Demographic features of 37 subjects with NF1-associated pheochromocytoma

 
Mutation analysis of the NF1 gene revealed 36 different germline mutations in 37 eligible subjects; only the mutation NF1 c. 1466 A/G was found in two unrelated subjects, associated with two different haplotypes (Table 2Go). None of the mutations were found in 100 healthy, ethnically matched, control subjects.

A total of 31 (86%) of the germline mutations were intra-exonic and splice site mutations. The spectrum of these point mutations comprised 17 truncating mutations (nonsense and frameshift type), nine affecting splicing, including NF1 c. 1466 A/G, creating a new splice site as described (26), and five missense mutations. The missense mutations all affected amino acids, which are conserved among human, mice, chicken, and Drosophila. Two of the five missense mutations (L90P, L578P) change the invariant amino acid leucine into proline, known as a helix-breaker in globular proteins (27), an exchange that may influence the secondary structure of NF1 protein. One mutation (L303R) affected a hydrophobic amino acid, which is present in mammals and Drosophila, changing it into a positively charged one. Cys 93 is mutated into a positively charged arginine, which lacks sulfhydryl groups (C93R). The fifth missense mutation is the exchange of a hydrophilic against a hydrophobic residue (S2580A).

Because of the phylogenetic conservation and the absence of these changes in healthy controls, these sequence variations can be classified as pathogenic missense mutations. Interestingly, one patient showed a homozygous 2-bp insertion (NF1 c. 2849 ins TT) in exon 16 of the NF1 gene. This result was repeated twice and also confirmed by using a second DNA probe from the patient’s blood. Her mother and grandmother were reported to have NF1, but blood DNA from them was not available. The patient’s father is unknown.

Of note, five (14%) of the germline mutations were large deletions or duplications. One patient was found to carry a deletion spanning exon 7 of the NF1 gene to exon 3 of the downstream RAB11.4 gene. Her phenotype did not appear different from the other deletion cases. Two patients had a single exon deletion of exon 12a and of exon 31, respectively, of the NF1 gene. In one patient, a deletion affecting exon 23b to exon 33 of the NF1 gene was detected, and one single exon duplication involving exon 15 was found in one patient.

The detected NF1 mutations, germline point mutations, as well as large deletions and duplications, were randomly distributed throughout the whole coding region of the NF1 gene, without any statistically significant correlations with mutational clustering or specific hot spot regions (Fig. 1Go). However, it is interesting to observe that although approximately one fourth of all reported NF1 cases had mutations within the cysteine-rich region [cysteine-serine rich domain (CSR)] and another one fourth within the RAS-GTPase activating protein domain (RGD) (28), 35% of our NF1-associated pheochromocytoma cases had mutations in the CSR and only 13% in the RGD (Fig. 1Go). The relative distribution of germline mutations within the RGD and CSR in our NF1-associated pheochromocytoma cases was reversed compared with that found historically among all NF1 cases (28) (P = 0.023).


Figure 1
View larger version (11K):
[in this window]
[in a new window]

  		FIG. 1. Spectrum of germline NF1 mutations in 37 eligible patients with pheochromocytoma and NF1. CSR, Comprising amino acid residues 543–909, in which three cysteine pairs (residues 622/632, 673/680, and 714/721) lie in a region for ATP binding 45 and has three cAMP-dependent protein kinase recognition sites phosphorylated by PKA; CTD, C-terminal domain; SEC14, domain in homologs of a Saccharomyces cerevisiae phosphatidylinositol transfer protein (Sec14p).

 
Because of relatively small numbers, it was difficult to tell whether there was a genotype-severity phenotype correlation. Severe NF1 was associated with one missense and seven truncating mutations (two insertions of one or two nucleotides, two stop codon, two splice site mutations, and one large deletion), intermediate NF1 with eight truncating mutations (two stop codon, one splice site, three large deletions/duplication, two insertion/deletion of five of one nucleotides), and mild NF1 with four missense and 17 truncating mutations (three stop codon, six insertions/deletions of up to four nucleotides, seven splice site mutations, and one large deletion). It is interesting to note that two unrelated individuals with NF1 and pheochromocytoma had identical mutations, Y489C (cases 8 and 9, Table 2Go). Yet, case 8 was operationally classified to have mild disease and case 9, severe.

LOH studies were performed for 21 blood/tumor pairs belonging to 19 patients with identified germline mutations (this study) and two additional NF1 patients in whom the germline mutation was not detected. LOH and, thus, inactivation of both NF1 alleles were found in 14 (67%) of the 21 paired pheochromocytoma/lymphocyte samples involving at least one of the four microsatellite markers spanning the NF1 region (Fig. 2Go). In contrast, no LOH was found in any of these four markers in 12 blood/tumor pairs belonging to sporadic pheochromocytoma (P = 0.0002).


Figure 2
View larger version (9K):
[in this window]
[in a new window]

  		FIG. 2. DHPLC chromatogram illustrating LOH at the D17S1849 marker. Upper panel represents tumor DNA and lower panel, blood-derived germline DNA. There is clear allelic loss in the tumor DNA (arrowheads for comparison), resulting in an altered melting temperature and, therefore, DHPLC profile.

 

   Discussion
Top
 Abstract
 Introduction
 Patients and Methods
 Results
 Discussion
References
 
Recent clinical-genetic studies have comprehensively analyzed the pheochromocytoma-associated syndromes MEN2, von Hippel-Lindau disease, PGL1, and PGL4, and have given us data for the fundamental understanding of these disorders. Many believe that both the complete mutational spectrum and equivalently documented clinical-genetic data have not been easily obtainable for pheochromocytoma in the setting of NF1 (4, 5, 29). One major reason is the low prevalence of pheochromocytoma in NF1 patients, approximately 0.1–5.7% (30, 31, 32). Thus, one needs about 2000 patients with NF1 to find 50 cases with pheochromocytoma. The other reason is the size of the NF1 gene, which is one of the largest in the human genome and difficult to analyze in the context of 36 pseudogenes. Therefore, mutation scanning for intra-exonic germline mutations, including the splice sites, as well as analyzing for large deletions or duplications pose a technical and logistical challenge because most studies in the PCR- based era cannot easily detect large deletions and rearrangements (33).

Our current study was able to overcome these challenges. First, and most importantly, we have, at our disposal, a large registry such that both clinical data and genetic data could be coupled. Second, we were able to design primers specific for the gene, avoiding amplification of the pseudogenes. Third, we were able to use the high throughput yet sensitive mutation scanning technology DHPLC. Finally, we extended our studies so that large deletions and rearrangements were systematically searched for, including fine, exon by exon deletion analysis using the highly sensitive quantitative real-time PCR approach.

Because of the low frequency of pheochromocytoma reported in NF1, there remains the question of whether pheochromocytoma is a true component of NF1 or a coincidental finding. One molecular clue that might help suggest that pheochromocytoma occurring in NF1 is a true component is to observe the loss of the remaining wild-type allele in NF1-related pheochromocytomas (20, 21, 22, 23). We believe that the 67% 17q LOH frequency in NF1-related pheochromocytoma compared with 0% in sporadic tumors (P = 0.0002) does provide molecular evidence that, indeed, pheochromocytoma is a true component of NF1.

In total, we detected germline NF1 mutations in 37 subjects with pheochromocytoma displaying the NF1 phenotype. To date, almost 80% of the 36 different germline mutations have not been previously described compared with 21%, which are summarized in the international database of NF1 mutations (http://www.nfmutation.org/). Of all germline mutations, 86% were intra-exonic and splice site mutations. In contrast with the previously reported 4–7% (34, 35) detected by fluorescence in situ hybridization or multiplex ligation-mediated probe amplification analysis, 14% were large deletions ranging from single exon deletion to nearly entire gene deletions (51 of 57 exons). Instead of the severe phenotype with dysmorphic features and intellectual impairment described for patients with large deletions, e.g. of 1.5 Mb of the NF1 gene and 11 adjacent genes, patients in our study with truncating mutations, including stop codons, frameshifts, and deletions ranging from single exon deletions to a loss of a major part of the NF1 gene, show a phenotype that does not differ from the phenotype caused by NF1 point mutations (36, 37). It is possible that the severity of NF1 phenotype might be modulated by differential deletion of the genes surrounding NF1 (38).

Despite almost 15 yr since the cloning of NF1, the full spectrum of its protein function is likely still not completely understood. One of the most important functional domains in neurofibromin, encoded by NF1, is the GAP related domain, which is encoded by exons 20–27a (Fig. 1Go) and has been found to interact with the RAS-GTPase p21ras (therefore, RAS-GAP domain or RGD) (39). Activation of p21ras by neurofibromin’s RGD stimulates GTP hydrolysis that can mediate the control of cellular proliferation (40, 41) and apoptosis (42). Consistently, missense mutations of the RGD with moderate reduction of GAP activity have already been reported (43) and may be sufficient to cause NF1.

Functional studies have demonstrated the role of NF1 in the pathogenesis of pheochromocytoma, and of the importance of the RGD in this regard (28, 36). To date, at least a quarter of NF1 mutations, mainly in series ascertained by NF1, are in the RGD. However, only 13% of the germline mutations in our series of pheochromocytoma patients who had NF1were within the RGD, in contrast to the 35% in the CSR. The relative distribution of mutations favoring CSR over RGD in our cases compared with historical reports is significant (P = 0.023). Consistent with our genetic observations here, there is recent emerging evidence that the CSR could be an equally important functional domain in neurofibromin. Using transfection experiments in human, rat, and avian central nervous system cells and cell lines, it has been shown that in response to epidermal growth factor, neurofibromin is phosphorylated on serine residues by protein kinase (PK) C (PKC) and that this phosphorylation was prominent in the CSR domain (44). They also showed that CSR can allosterically regulate RGD dependent on PKC-mediated neurofibromin phosphorylation of the serines within the CSR. The CSR also has three cysteine pairs suggestive of a region for ATP binding and has three cAMP-dependent PK recognition sites phosphorylated by PKA (45). Interestingly, the regulatory subunit 1 {alpha} of PKA is encoded by a gene (PRKAR1A), which when mutated in the germline, causes a subset of Carney complex, another neural crest-associated phakomatosis (46). These and our genetic data suggest that the CSR could be a prominent mutational target, at least in NF1-associated pheochromocytoma, and perhaps more universally in all heritable and sporadic pheochromocytoma as well.

In summary, we have documented the germline NF1 mutational spectra in 37 subjects with pheochromocytoma and NF1. In contrast to the previously described mutational spectra of NF1 cases, we have shown that NF1-associated pheochromocytoma patients have germline NF1 mutations that favor the CSR over the RGD. These genetic data might help direct functional evaluation of neurofibromin in its role in both heritable and sporadic pheochromocytoma and paraganglial tumors.


   Acknowledgments
 
The members of the Neurofibromatosis Type 1 and Pheochromocytoma-Study-Group are: B. Allolio, Würzburg; M. Brauckhoff, Halle; I. Cybulska, Warsaw; H. G. L. Divona, Rome; H. Dralle, Halle; S. Filetti, Rome; C. Fottner, Mainz; S. Giustini, Rome; W. Januszewicz, Warsaw; M. Klein, Nancy; W. Krone, Köln; M. Lapinski, Warsaw; I. Lon, Warsaw; M. Makowiecka-Ciesla, Warsaw; K. Mann, Essen; M. Muresan, Nancy; S. Petersenn, Essen; M. Reincke, Munich; M. Sznajderman, Warsaw; M. Weber, Mainz; G. Weryha, Nancy; S. Bornstein, Dresden; and B. Wocial, Warsaw.

The members of the Neurofibromatosis Type 1 Study-Group are: R. Stadler, Minden; H. Ising, Sindelfingen; J. Kunze, Duisburg; D. Hördemann-Ebler, Gaggenau; T. Bierwirth, Bielefeld; H. Engler, Freiburg; B. Merdausl, Kempen; H.-G. Bongartz, Fritzlar; U. Wlotzke, Ulm; R. Leitz, Stuttgart; A. Rübben, Aachen; G. Hübner, Halle; T. Schwarz, Kiel; E. Wassmer, Augsburg; J. Nekwasil, Nordhausen; J. Reifenberger, Düsseldorf; H. Kirchesch, Pulheim; M. Schlaeger, Oldenburg; R. Barth, Kirchzarten; and C. G. Schirren, Darmstadt.

We thank B. Wehrle (technician), M. Buchta (technician), M. Sullivan, Ph.D., G. Franke, Ph.D., G. Schluh (research assistant), and Z. Nabulsi and S. Schonhardt (study nurses) for their excellent assistance. We also thank the German Neurofibromatosis Self Support Group for its support.


   Footnotes
 
This work was supported by Deutsche Krebshilfe (70-3313-Ne 1, to H.P.H.N.), the Deutsche Forschungsgemeinschaft (NE 571/5-3, to H.P.H.N.), the European Union (LSHC-CT-2005-518200, to H.P.H.N.), and the National Institutes of Health, Bethesda, Maryland (R01HD39058-04 and R01HD39058-04S1, to C.E.). C.E. is a recipient of the Doris Duke Distinguished Clinical Scientist Award.

Disclosure Summary: B.B., W.B., V.F.M., M.H.H., D.B., M.R., A.C., T.H., F.S., C.P., M.P., C.L., S.C., G.A., R.D.K.-N., N.R., A.F., L.B., M.A.W., M.Ma., G.M., F.F.P., M.B., M.K.W., B.K., G.B., R.P., A.-C.K., F.L., M.Mo., O.G., B.J., S.R.M., G.O., A.J., J.K., C.E., and H.P.H.N. have nothing to declare. Nobody was previously employed by a company or has equity interests. Nobody consulted for a company. Nobody was previously employed or received lecture fees from a company. Nobody is an inventor on a patent.

First Published Online April 10, 2007

1 For a list of members of the European-American Phaeochromocytoma Registry and Study Group, see Acknowledgments. Back

Abbreviations: CSR, Cysteine-serine rich domain; DHPLC, denaturing HPLC analysis; LOH, loss-of-heterozygosity; MEN2, multiple endocrine neoplasia type 2; NF1, neurofibromatosis type 1; PGL, paraganglioma syndrome; PK, protein kinase; RGD, RAS-GTPase activating protein domain.

Received December 21, 2006.

Accepted April 3, 2007.


   References
Top
 Abstract
 Introduction
 Patients and Methods
 Results
 Discussion
 References
 

  1. Bausch B, Borozdin W, Neumann HPH, European-American Pheochromocytoma Study G 2006 Clinical and genetic characteristics of patients with neurofibromatosis type 1 and pheochromocytoma. N Engl J Med 354:2729–2731[Free Full Text]
  2. Bausch B, Koschker A-C, Fassnacht M, Stoevesandt J, Hoffmann MM, Eng C, Allolio B, Neumann HPH 2006 Comprehensive mutation scanning of NF1 in apparently sporadic cases of pheochromocytoma. J Clin Endocrinol Metab 91:3478–3481[Abstract/Free Full Text]
  3. Eng C, Hampel H, de la Chapelle A 2001 Genetic testing for cancer predisposition. Annu Rev Med [Erratum (2002) 53:xi] 52:371–400
  4. Neumann HP, Bausch B, McWhinney SR, Bender BU, Gimm O, Franke G, Schipper J, Klisch J, Altehoefer C, Zerres K, Januszewicz A, Eng C, Smith WM, Munk R, Manz T, Glaesker S, Apel TW, Treier M, Reineke M, Walz MK, Hoang-Vu C, Brauckhoff M, Klein-Franke A, Klose P, Schmidt H, Maier-Woelfle M, Peczkowska M, Szmigielski C, Eng C, Freiburg-Warsaw-Columbus Pheochromocytoma Study G 2002 Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med 346:1459–1466[Abstract/Free Full Text]
  5. Neumann HP, Pawlu C, Peczkowska M, Bausch B, McWhinney SR, Muresan M, Buchta M, Franke G, Klisch J, Bley TA, Hoegerle S, Boedeker CC, Opocher G, Schipper J, Januszewicz A, Eng C, European-American Paraganglioma Study G 2004 Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. JAMA [Erratum (2004) 292:1686] 292:943–951
  6. 1988 Neurofibromatosis. Conference statement. National Institutes of Health Consensus Development Conference. Arch Neurol 45:575–578
  7. Gutmann DH, Aylsworth A, Carey JC, Korf B, Marks J, Pyeritz RE, Rubenstein A, Viskochil D 1997 The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA 278:51–57[Abstract/Free Full Text]
  8. Barker D, Wright E, Nguyen K, Cannon L, Fain P, Goldgar D, Bishop DT, Carey J, Baty B, Kivlin J, Willard H, Wayes JS, Greig G, Leinwand L, Nakamura Y, O’Conell P, Leppert M, Lalouel JM, White R, Skolnick M 1987 Gene for von Recklinghausen neurofibromatosis is in the pericentromeric region of chromosome 17. Science 236:1100–1102[Abstract/Free Full Text]
  9. Seizinger BR, Rouleau GA, Ozelius LJ, Lane AH, Faryniarz AG, Chao MV, Huson S, Korf BR, Parry DM, Pericak-Vance MA, Collins FS, Hobbs WJ, Falcone BG, Iannazzi JA, Roy JC, St George-Hyslop PH, Tanzi RE, Bothwell MA, Upadhyaya M, Harper P, Goldstein AE, Hoover DL, Bader JL, Spence MA, Mulvihill JJ, Aylsworth AS, Vance JM, Rossenwasser GOD, Gaskell PC, Roses AD, Martuza RL, Breakefield XO, Gusella JF 1987 Genetic linkage of von Recklinghausen neurofibromatosis to the nerve growth factor receptor gene. Cell 49:589–594[CrossRef][Medline]
  10. Cawthon RM, Weiss R, Xu GF, Viskochil D, Culver M, Stevens J, Robertson M, Dunn D, Gesteland R, O’Connell P, White R 1990 A major segment of the neurofibromatosis type 1 gene: cDNA sequence, genomic structure, and point mutations. Cell [Erratum (1990) 62:following 608] 62:193–201
  11. Danglot G, Teinturier C, Duverger A, Bernheim A 1994 Tissue-specific alternative splicing of neurofibromatosis 1 (NF1) mRNA. Biomed Pharmacother 48:365–372[CrossRef][Medline]
  12. Scheurlen WG, Senf L 1995 Analysis of the GAP-related domain of the neurofibromatosis type 1 (NF1) gene in childhood brain tumors. Int J Cancer 64:234–238[Medline]
  13. Kehrer-Sawatzki H, Schwickardt T, Assum G, Rocchi M, Krone W 1997 A third neurofibromatosis type 1 (NF1) pseudogene at chromosome 15q11.2. Hum Genet 100:595–600[CrossRef][Medline]
  14. Legius E, Marchuk DA, Hall BK, Andersen LB, Wallace MR, Collins FS, Glover TW 1992 NF1-related locus on chromosome 15. Genomics 13:1316–1318[CrossRef][Medline]
  15. Luijten M, Fahsold R, Mischung C, Westerveld A, Nurnberg P, Hulsebos TJ 2001 Limited contribution of interchromosomal gene conversion to NF1 gene mutation. J Med Genet 38:481–485[Free Full Text]
  16. Luijten M, Wang Y, Smith BT, Westerveld A, Smink LJ, Dunham I, Roe BA, Hulsebos TJ 2000 Mechanism of spreading of the highly related neurofibromatosis type 1 (NF1) pseudogenes on chromosomes 2, 14 and 22. Eur J Hum Genet 8:209–214[CrossRef][Medline]
  17. Purandare SM, Huntsman Breidenbach H, Li Y, Zhu XL, Sawada S, Neil SM, Brothman A, White R, Cawthon R, Viskochil D 1995 Identification of neurofibromatosis 1 (NF1) homologous loci by direct sequencing, fluorescence in situ hybridization, and PCR amplification of somatic cell hybrids. Genomics 30:476–485[CrossRef][Medline]
  18. Regnier V, Meddeb M, Lecointre G, Richard F, Duverger A, Nguyen VC, Dutrillaux B, Bernheim A, Danglot G 1997 Emergence and scattering of multiple neurofibromatosis (NF1)-related sequences during hominoid evolution suggest a process of pericentromeric interchromosomal transposition. Hum Mol Genet 6:9–16[Abstract/Free Full Text]
  19. Suzuki H, Ozawa N, Taga C, Kano T, Hattori M, Sakaki Y 1994 Genomic analysis of a NF1-related pseudogene on human chromosome 21. Gene 147:277–280[CrossRef][Medline]
  20. Koch CA, Pacak K, Chrousos GP 2002 The molecular pathogenesis of hereditary and sporadic adrenocortical and adrenomedullary tumors. J Clin Endocrinol Metab 87:5367–5384[Abstract/Free Full Text]
  21. Jacks T, Shih TS, Schmitt EM, Bronson RT, Bernards A, Weinberg RA 1994 Tumour predisposition in mice heterozygous for a targeted mutation in Nf1. Nat Genet 7:353–361[CrossRef][Medline]
  22. Xu W, Mulligan LM, Ponder MA, Liu L, Smith BA, Mathew CG, Ponder BA 1992 Loss of NF1 alleles in phaeochromocytomas from patients with type I neurofibromatosis. Genes Chromosomes Cancer 4:337–342[Medline]
  23. Gutmann DH, Cole JL, Stone WJ, Ponder BA, Collins FS 1994 Loss of neurofibromin in adrenal gland tumors from patients with neurofibromatosis type I. Genes Chromosomes Cancer 10:55–58[Medline]
  24. Boehm D, Herold S, Kuechler A, Liehr T, Laccone F 2004 Rapid detection of subtelomeric deletion/duplication by novel real-time quantitative PCR using SYBR-green dye. Hum Mutat 23:368–378[CrossRef][Medline]
  25. Borozdin W, Boehm D, Leipoldt M, Wilhelm C, Reardon W, Clayton-Smith J, Becker K, Muhlendyck H, Winter R, Giray O, Silan F, Kohlhase J 2004 SALL4 deletions are a common cause of Okihiro and acro-renal-ocular syndromes and confirm haploinsufficiency as the pathogenic mechanism. J Med Genet 41:e113
  26. Messiaen LM, Callens T, Roux KJ, Mortier GR, De Paepe A, Abramowicz M, Pericak-Vance MA, Vance JM, Wallace MR 1999 Exon 10b of the NF1 gene represents a mutational hotspot and harbors a recurrent missense mutation Y489C associated with aberrant splicing. Genet Med 1:248–253[Medline]
  27. Barlow DJ, Thornton JM 1988 Helix geometry in proteins. J Mol Biol 201:601–619[CrossRef][Medline]
  28. Fahsold R, Hoffmeyer S, Mischung C, Gille C, Ehlers C, Kucukceylan N, Abdel-Nour M, Gewies A, Peters H, Kaufmann D, Buske A, Tinschert S, Nurnberg P 2000 Minor lesion mutational spectrum of the entire NF1 gene does not explain its high mutability but points to a functional domain upstream of the GAP-related domain. Am J Hum Genet 66:790–818[CrossRef][Medline]
  29. Benn DE, Gimenez-Roqueplo A-P, Reilly JR 2006 Clinical presentation and penetrance of pheochromocytoma/paraganglioma syndromes. J Clin Endocrinol Metab 91:827–836[Abstract/Free Full Text]
  30. Hope DG, Mulvihill JJ 1981 Malignancy in neurofibromatosis. Adv Neurol 29:33–56[Medline]
  31. Riccardi VM 1981 Von Recklinghausen neurofibromatosis. N Engl J Med 305:1617–1627[Medline]
  32. Walther MM, Herring J, Enquist E, Keiser HR, Linehan WM 1999 von Recklinghausen’s disease and pheochromocytomas. J Urol 162:1582–1586[CrossRef][Medline]
  33. De Luca A, Buccino A, Gianni D, Mangino M, Giustini S, Richetta A, Divona L, Calvieri S, Mingarelli R, Dallapiccola B 2003 NF1 gene analysis based on DHPLC. Hum Mutat 21:171–172[Medline]
  34. Kluwe L, Siebert R, Gesk S, Friedrich RE, Tinschert S, Kehrer-Sawatzki H, Mautner VF 2004 Screening 500 unselected neurofibromatosis 1 patients for deletions of the NF1 gene. Hum Mutat 23:111–116[CrossRef][Medline]
  35. Wimmer K, Yao S, Claes K, Kehrer-Sawatzki H, Tinschert S, De Raedt T, Legius E, Callens T, Beiglbock H, Maertens O, Messiaen L 2006 Spectrum of single- and multiexon NF1 copy number changes in a cohort of 1,100 unselected NF1 patients. Genes Chromosomes Cancer 45:265–276[CrossRef][Medline]
  36. Upadhyaya M, Han S, Consoli C, Majounie E, Horan M, Thomas NS, Potts C, Griffiths S, Ruggieri M, von Deimling A, Cooper DN 2004 Characterization of the somatic mutational spectrum of the neurofibromatosis type 1 (NF1) gene in neurofibromatosis patients with benign and malignant tumors. Hum Mutat 23:134–146[CrossRef][Medline]
  37. Cnossen MH, van der Est MN, Breuning MH, van Asperen CJ, Breslau-Siderius EJ, van der Ploeg AT, de Goede-Bolder A, van den Ouweland AM, Halley DJ, Niermeijer MF 1997 Deletions spanning the neurofibromatosis type 1 gene: implications for genotype-phenotype correlations in neurofibromatosis type 1? Hum Mutat 9:458–464[CrossRef][Medline]
  38. Jenne DE, Tinschert S, Reimann H, Lasinger W, Thiel G, Hameister H, Kehrer-Sawatzki H 2001 Molecular characterization and gene content of breakpoint boundaries in patients with neurofibromatosis type 1 with 17q11.2 microdeletions. Am J Hum Genet 69:516–527[CrossRef][Medline]
  39. Martin GA, Viskochil D, Bollag G, McCabe PC, Crosier WJ, Haubruck H, Conroy L, Clark R, O’Connell P, Cawthon RM, et al 1990 The GAP-related domain of the neurofibromatosis type 1 gene product interacts with ras p21. Cell 63:843–849[CrossRef][Medline]
  40. Dasgupta B, Dugan LL, Gutmann DH 2003 The neurofibromatosis 1 gene product neurofibromin regulates pituitary adenylate cyclase-activating polypeptide-mediated signaling in astrocytes. J Neurosci 23:8949–8954[Abstract/Free Full Text]
  41. Zhu Y, Parada LF 2001 Neurofibromin, a tumor suppressor in the nervous system. Exp Cell Res 264:19–28[CrossRef][Medline]
  42. Lee S, Nakamura E, Yang H, Wei W, Linggi MS, Sajan MP, Farese RV, Freeman RS, Carter BD, Kaelin Jr WG, Schlisio S 2005 Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: developmental culling and cancer. Cancer Cell 8:155–167[CrossRef][Medline]
  43. Upadhyaya M, Osborn MJ, Maynard J, Kim MR, Tamanoi F, Cooper DN 1997 Mutational and functional analysis of the neurofibromatosis type 1 (NF1) gene. Hum Genet 99:88–92[Medline]
  44. Mangoura D, Sun Y, Li C, Singh D, Gutmann DH, Flores A, Ahmed M, Vallianatos G 2006 Phosphorylation of neurofibromin by PKC is a possible molecular switch in EGF receptor signaling in neural cells. Oncogene 25:735–745[CrossRef][Medline]
  45. Feng L, Yunoue S, Tokuo H, Ozawa T, Zhang D, Patrakitkomjorn S, Ichimura T, Saya H, Araki N 2004 PKA phosphorylation and 14–3-3 interaction regulate the function of neurofibromatosis type I tumor suppressor, neurofibromin. FEBS Lett 557:275–282[CrossRef][Medline]
  46. Kirschner LS, Carney JA, Pack SD, Taymans SE, Giatzakis C, Cho YS, Cho-Chung YS, Stratakis CA 2000 Mutations of the gene encoding the protein kinase A type I-{alpha} regulatory subunit in patients with the Carney complex. Nat Genet 26:89–92[CrossRef][Medline]



This article has been cited by other articles:


Home page
 J. Clin. Endocrinol. Metab.Home page
M. Mannelli, M. Castellano, F. Schiavi, S. Filetti, M. Giacche, L. Mori, V. Pignataro, G. Bernini, V. Giache, A. Bacca, et al.
Clinically Guided Genetic Screening in a Large Cohort of Italian Patients with Pheochromocytomas and/or Functional or Nonfunctional Paragangliomas
J. Clin. Endocrinol. Metab., May 1, 2009; 94(5): 1541 - 1547.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
A. Karagiannis, D. P Mikhailidis, V. G Athyros, and F. Harsoulis
Pheochromocytoma: an update on genetics and management
Endocr. Relat. Cancer, December 1, 2007; 14(4): 935 - 956.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bausch, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bausch, B.
Related Collections
Right arrow Adrenal and Hypertension
Right arrow Endocrine Oncology

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals